{
  "zip": "H3Z 3B8",
  "sector": "",
  "longBusinessSummary": "Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; NERLYNX for the treatment of HER2-positive breast cancer; and Trelstar for prostate cancer. It also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; NeurAxon family for acute migraine, pain and neurological disorders; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to tre Ibsrela at tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; Burinex for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease; Impavido, an oral drug treatment based on miltefosine for the visceral, cutaneous, and mucocutaneous leishmaniasis; and Imvexxy for moderate-to-severe dyspareunia and Bijuva for moderate-to-severe vasomotor symptoms due to menopause. It develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. It develops TULSA-PRO, a medical device for prostate ablation. It finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.",
  "city": "Montreal",
  "phone": "514 484 4483",
  "state": "QC",
  "country": "Canada",
  "companyOfficers": [],
  "website": "http://www.gud-knight.com",
  "maxAge": 1,
  "address1": "3400 De Maisonneuve Boulevard West",
  "fax": "514 481 4116",
  "industry": "",
  "address2": "Suite 1055",
  "previousClose": 4.15784,
  "regularMarketOpen": 4.25382,
  "twoHundredDayAverage": 4.5463886,
  "trailingAnnualDividendYield": null,
  "payoutRatio": null,
  "volume24Hr": null,
  "regularMarketDayHigh": 4.25382,
  "navPrice": null,
  "averageDailyVolume10Day": 3137,
  "totalAssets": null,
  "regularMarketPreviousClose": 4.15784,
  "fiftyDayAverage": 4.180303,
  "trailingAnnualDividendRate": null,
  "open": 4.25382,
  "averageVolume10days": 3137,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 0.726072,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 4.25382,
  "priceHint": 4,
  "currency": "USD",
  "trailingPE": 26.097054,
  "regularMarketVolume": 562,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 598878272,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 5353,
  "priceToSalesTrailing12Months": null,
  "dayLow": 4.25382,
  "ask": 0,
  "ytdReturn": null,
  "askSize": 0,
  "volume": 562,
  "fiftyTwoWeekHigh": 6.003,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 3.44,
  "bid": 0,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": 0,
  "dayHigh": 4.25382,
  "exchange": "PNK",
  "shortName": "KNIGHT THERAPEUTICS INC",
  "longName": "Knight Therapeutics Inc.",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "KHTRF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_254910893",
  "uuid": "d2bf5429-6fdb-3507-845a-727fb6483ab9",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": 0.14959,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 142844000,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": 5.37,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1577750400,
  "heldPercentInstitutions": 0.28244,
  "netIncomeToCommon": null,
  "trailingEps": 0.163,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": 0.79214525,
  "heldPercentInsiders": 0.17731,
  "nextFiscalYearEnd": 1640908800,
  "mostRecentQuarter": 1601424000,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 97300361,
  "enterpriseValue": 541238208,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 4.25382,
  "logo_url": "https://logo.clearbit.com/gud-knight.com"
}